📊 PULM Key Takeaways
Is Pulmatrix, Inc. (PULM) a Good Investment?
Pulmatrix is a pre-commercial pharmaceutical company with $53K in revenue against $1.2M in net losses, exhibiting unsustainable cash burn of $1.1M annually against a $3.3M cash reserve (~3-year runway). The company faces binary clinical/development risk with no near-term profitability path and will likely require dilutive capital raises to fund operations.
Pulmatrix, Inc. Key Strengths (PULM)
- Clean balance sheet with zero long-term debt
- Strong liquidity position (4.96x current ratio) providing operational buffer
- Revenue growth of 1571.5% YoY and net loss improvement of 46% YoY suggest positive traction
PULM Stock Risks: Pulmatrix, Inc. Investment Risks
- Unsustainable cash burn rate ($1.1M annually) relative to $53K revenue base and limited runway
- Pre-commercial pharmaceutical company with binary clinical development outcomes and regulatory risks
- Will require dilutive capital raises to continue operations; zero insider buying activity suggests limited confidence
- Operating margin of -2438% indicates business model not yet viable at scale
Key Metrics to Watch
- Quarterly cash burn trends and cash runway depletion rate
- Clinical trial progress milestones and regulatory developments
- Path to revenue scaling and timeline to positive operating cash flow
Pulmatrix, Inc. (PULM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.96x current ratio provides a solid financial cushion.
PULM Profit Margin, ROE & Profitability Analysis
PULM vs Healthcare Sector: How Pulmatrix, Inc. Compares
How Pulmatrix, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pulmatrix, Inc. Stock Overvalued? PULM Valuation Analysis 2026
Based on fundamental analysis, Pulmatrix, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pulmatrix, Inc. Balance Sheet: PULM Debt, Cash & Liquidity
PULM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pulmatrix, Inc.'s revenue has declined by 38% over the 5-year period, indicating business contraction. The most recent EPS of $-2.62 indicates the company is currently unprofitable.
PULM Revenue Growth, EPS Growth & YoY Performance
PULM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $366.0K | $825.0K | $-0.24 |
| Q2 2025 | $1.6M | $825.0K | $-0.42 |
| Q1 2025 | $5.9M | $825.0K | $0.23 |
| Q3 2024 | $366.0K | $825.0K | $-0.71 |
| Q2 2024 | $1.6M | $825.0K | $-1.04 |
| Q1 2024 | $1.5M | $825.0K | $0.23 |
| Q3 2023 | $1.8M | -$3.8M | $-1.03 |
| Q2 2023 | $1.3M | -$3.8M | $-1.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pulmatrix, Inc. Dividends, Buybacks & Capital Allocation
PULM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pulmatrix, Inc. (CIK: 0001574235)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PULM
What is the AI rating for PULM?
Pulmatrix, Inc. (PULM) has an AI grade of D with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PULM's key strengths?
Claude: Clean balance sheet with zero long-term debt. Strong liquidity position (4.96x current ratio) providing operational buffer.
What are the risks of investing in PULM?
Claude: Unsustainable cash burn rate ($1.1M annually) relative to $53K revenue base and limited runway. Pre-commercial pharmaceutical company with binary clinical development outcomes and regulatory risks.
What is PULM's revenue and growth?
Pulmatrix, Inc. reported revenue of $53.0K.
Does PULM pay dividends?
Pulmatrix, Inc. does not currently pay dividends.
Where can I find PULM SEC filings?
Official SEC filings for Pulmatrix, Inc. (CIK: 0001574235) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PULM's EPS?
Pulmatrix, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PULM's fundamental grade?
Based on our AI fundamental analysis in May 2026, Pulmatrix, Inc. has a D grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PULM stock overvalued or undervalued?
Valuation metrics for PULM: ROE of -32.6% (sector avg: 15%), net margin of -2,211.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PULM's AI grade for 2026?
Our dual AI analysis gives Pulmatrix, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PULM's free cash flow?
Pulmatrix, Inc.'s operating cash flow is $-1.1M, with capital expenditures of $398.0K. FCF margin is -2,764.2%.
How does PULM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,211.3% (avg: 12%), ROE -32.6% (avg: 15%), current ratio 4.96 (avg: 2).